Conference Reports for NATAP

13th IAS Conference on HIV Science IAS 2026 July 26-31 Rio, Brazil Back

Efficacy and Safety of Twice-Yearly Lenacapavir, Teropavimab, and Zinlirvimab as an HIV-1 Treatment for Up To 104 Weeks       IAS 2026 Rio, Brazil